Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589014 | 0.89 | — | — | |
| SCHEMBL14578307 | 0.88 | PRMT3 (0.35) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18892539 | 0.85 | — | — | |
| SCHEMBL14578314 | 0.76 | PRMT3 (0.40) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12901248 | 0.73 | PRMT3 (0.38) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL2733533 | 0.73 | — | — | |
| SCHEMBL24764770 | 0.71 | — | — | |
| SCHEMBL10330868 | 0.71 | — | — | |
| SCHEMBL14578406 | 0.70 | — | — | |
| SCHEMBL15919032 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045027-A1 | Adjuvant | GLAXO GROUP LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-7772413-B2 | Amide and peptide derivatives of tetraalkylenepentamines as transfection agents | GLAXO GROUP LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090149401-A1 | AMIDE AND PEPTIDE DERIVATIVES OF TETRAALKYLENEPENTAMINES AS TRANSFECTION AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045027-A1 | Adjuvant | TLR3, TLR9, TLR7 | PRMT3 2680/4885CARM1 3515/4885PRMT6 3689/4885 |
| US-20090149401-A1 | AMIDE AND PEPTIDE DERIVATIVES OF TETRAALKYLENEPENTAMINES AS TRANSFECTION AGENTS | PCTP, PHOSPHO1, PLTP | PRMT3 2721/4885CARM1 4508/4885PRMT6 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.